5.35
+0.09(+1.71%)
Currency In USD
| Previous Close | 5.26 |
| Open | 5.31 |
| Day High | 5.39 |
| Day Low | 5.26 |
| 52-Week High | 9.33 |
| 52-Week Low | 4.02 |
| Volume | 4.93M |
| Average Volume | 4.28M |
| Market Cap | 1.28B |
| PE | -31.47 |
| EPS | -0.17 |
| Moving Average 50 Days | 5.12 |
| Moving Average 200 Days | 5.51 |
| Change | 0.09 |
If you invested $1000 in Ardelyx, Inc. (ARDX) 10 years ago, it would be worth $1,883.8 as of April 29, 2025 at a share price of $5.35. Whereas If you bought $1000 worth of Ardelyx, Inc. (ARDX) shares 5 years ago, it would be worth $2,786.46 as of April 29, 2025 at a share price of $5.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
GlobeNewswire Inc.
Apr 24, 2025 12:01 PM GMT
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical need
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
GlobeNewswire Inc.
Apr 17, 2025 12:00 PM GMT
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-clas
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
GlobeNewswire Inc.
Apr 10, 2025 8:02 PM GMT
WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical need